- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Patent holdings for IPC class C07D 413/14
Total number of patents in this class: 11629
10-year publication summary
|
751
|
720
|
744
|
872
|
887
|
885
|
900
|
984
|
878
|
378
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4892 |
312 |
| Novartis AG | 10904 |
234 |
| Boehringer Ingelheim International GmbH | 4704 |
232 |
| Merck Sharp & Dohme LLC | 3741 |
230 |
| F. Hoffmann-La Roche AG | 7926 |
204 |
| Gilead Sciences, Inc. | 2028 |
185 |
| Takeda Pharmaceutical Company Limited | 2704 |
159 |
| Merck Patent GmbH | 5850 |
151 |
| Janssen Pharmaceutica N.V. | 3423 |
142 |
| AstraZeneca AB | 2928 |
132 |
| Hoffmann-La Roche Inc. | 3379 |
123 |
| Amgen Inc. | 4047 |
123 |
| Pfizer Inc. | 3367 |
103 |
| Rigel Pharmaceuticals, Inc. | 540 |
94 |
| Vertex Pharmaceuticals Incorporated | 1596 |
86 |
| Genentech, Inc. | 3961 |
83 |
| LG Chem, Ltd. | 17561 |
72 |
| Bayer Pharma AG | 1061 |
67 |
| Syngenta Participations AG | 1919 |
66 |
| Glaxosmithkline Intellectual Property Development Limited | 753 |
64 |
| Other owners | 8767 |